Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript
08:33am, Wednesday, 19'th Nov 2025
Alnylam Pharmaceuticals, Inc. ( ALNY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 18'th Nov 2025
Here is how Alnylam Pharmaceuticals (ALNY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Banco Bilbao Vizcaya Argentaria S.A.
04:43am, Sunday, 16'th Nov 2025
Banco Bilbao Vizcaya Argentaria S.A. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 2.2% in the undefined quarter, according to its most recent disclosure with the S
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money
05:40am, Tuesday, 11'th Nov 2025
Alnylam Pharmaceuticals boasts an exciting product lineup and pipeline. IonQ could be one of the biggest winners in the fast-growing quantum computing market.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript
12:41pm, Monday, 10'th Nov 2025
Alnylam Pharmaceuticals, Inc. ( ALNY ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study
American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors
08:10am, Wednesday, 05'th Nov 2025
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive p
Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak
03:58pm, Friday, 31'st Oct 2025
Alnylam Pharmaceuticals, Inc. delivered strong Q3 results, driven by Amvuttra's success in ATTR-CM, with total revenues soaring to $1.25 billion. ALNY's market cap surged to $59B as Amvuttra outperfor
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
12:20pm, Friday, 31'st Oct 2025
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript
02:46pm, Thursday, 30'th Oct 2025
Alnylam Pharmaceuticals, Inc. ( ALNY ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christine Lindenboom - Chief Corporate Communications Officer Yvonne Greenstreet - CEO &
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday?
02:39pm, Thursday, 30'th Oct 2025
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) stock is trading lower after the company reported third-quarter earnings.
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
11:30am, Thursday, 30'th Oct 2025
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Str
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
10:18am, Thursday, 30'th Oct 2025
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to a loss of $0.5 per share a year ago.
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
08:00am, Thursday, 30'th Oct 2025
Alnylam stock could surge again after the biotech company easily beat Wall Street's third-quarter forecasts on the back of Amvuttra.
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
08:00am, Thursday, 30'th Oct 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended Se
